David D. Biggs

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi et al. · Journal of Clinical Oncology · 2012 · 519 citations · Full text

Medicine, Oncology, Pharmacology +17

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy et al. · New England Journal of Medicine · 2016 · 450 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Sandra M. Swain, Gong Tang, Charles E. Geyer et al. · Journal of Clinical Oncology · 2013 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Ethan Basch, Amylou C. Dueck, Lauren J. Rogak et al. · JAMA Oncology · 2017 · 133 citations · Full text

Nursing, Oncology, Cancer Symptom Management +15

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2

Patricia A. Ganz, Edward H. Romond, Reena S. Cecchini et al. · Journal of Clinical Oncology · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17